Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising drug targets HER2 cancers in new trial

NCT ID NCT07192068

Recruiting now Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests zanidatamab, a drug that targets cancer cells with a HER2 gene alteration, in 105 adults with advanced lung, endometrial, colorectal, head & neck, or sarcoma cancers. Participants receive the drug every 3 weeks, and doctors monitor tumor shrinkage and side effects. The goal is to see if zanidatamab can shrink or stabilize these tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Zanidatamab
What this could lead to
If successful, this could offer a new treatment option for several hard-to-treat cancers that have a specific HER2 gene change.
What could go wrong
This is a mid-stage trial with only 105 participants, so results may not apply to everyone. Zanidatamab can cause side effects, and not all patients may see tumor shrinkage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal carcinoma colorectal neoplasm endometrial cancer endometrium neoplasm head and neck cancer Head and Neck Neoplasms non-small cell lung carcinoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CARCINOMA ENDOMETRIAL HEAD & NECK CANCER NON-SMALL CELL LUNG CANCER SARCOMA

Contacts and locations

Locations

  • Chu Timone

    RECRUITING

    Marseille, France

  • Gustave Roussy

    RECRUITING

    Villejuif, France

  • Institut de Cancérologie de Lorraine

    ACTIVE_NOT_RECRUITING

    Vandœuvre-lès-Nancy, France

  • Institut de Cancérologie de l'Ouest

    ACTIVE_NOT_RECRUITING

    Angers, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.